What Can You Expect in 2027?
The 3rd TRP Target Selection & Drug Design Summit brings the specialists making these decisions into one room for three days of focused scientific exchange. This is the industry’s only meeting exclusively dedicated to dive deep into the discovery and preclinical questions unique to radiopharmaceutical development to challenge assumptions, compare approaches and pressure-test development strategies with peers.
Expect interactive workshops, technical case studies, expert panels, scientific posters and dedicated networking designed to move beyond high-level discussion and get into the decisions shaping real RLT programmes.
Expand the Search for Differentiated Targets
Look beyond established RLT biology and explore how emerging targets, clinically validated targets from other modalities and advanced imaging approaches can provide new starting points for radiopharmaceutical development.
Pressure-Test Your Drug Design Decisions
Compare how peers are approaching targeting moieties, binders, linkers, chelators and radionuclide selection, and examine how these interconnected choices can be optimised around the biology of the target and intended therapeutic profile.
Generate Evidence That Supports Better Decisions
Explore how biodistribution, dosimetry, radiobiology, toxicology and predictive preclinical models can be used to answer the questions that matter before significant time and capital are committed to clinical development.
Learn From the Entire Preclinical Value Chain
Connect discovery biology with medicinal chemistry, radiochemistry, imaging, DMPK, toxicology and dosimetry to understand how decisions made in one function impact the rest of the development programme.
Build the Ultimate Preclinical Network
With 100+ experts across the preclinical RLT ecosystem, speed networking, facilitated 1-2-1 introductions, a scientific poster session and dedicated networking breaks create multiple opportunities to meet collaborators, benchmark approaches and build new partnerships.
Leave Boston with new approaches to investigate, development decisions to challenge and a stronger network of experts to draw on as you build the next generation of radiopharmaceuticals.
![Speakers-Image-1-1024x576[1]](https://targeted-radiopharma-target-selection-drug-design.com/wp-content/uploads/sites/228/2026/10/Speakers-Image-1-1024x5761-1.png "Speakers-Image-1-1024x576[1]")
![CBCDx-0747[1]](https://targeted-radiopharma-target-selection-drug-design.com/wp-content/uploads/sites/228/2026/10/CBCDx-07471.jpg "CBCDx-0747[1]")
Key Focus Areas Include:
Leveraging Clinically Validated Targets to De-Risk RLT Target Selection
Look beyond traditional radiopharmaceutical target discovery and assess clinically validated targets from ADCs, bispecifics, T-cell engagers, targeted antibodies & RDCs. Determine what evidence is transferable across modalities and when validation is strong enough to justify progression into an RLT program
Harnessing Kinetic Imaging to Strengthen Target Characterisation & Validation
Combine total-body PET, digital SPECT, computational biology, multi-omics & quantitative imaging to understand target expression, heterogeneity and in vivo behaviour over time, distinguishing targets that simply image well from those with genuine therapeutic potential
Interrogating Emerging Biology to Identify the Next Generation of RLT Targets
Move beyond increasingly established target landscapes by exploring CAIX, MSLN, the brain, ECM & leukocytes, and determine how expression, replenishment and internalization influence suitability for radiopharmaceutical development.
Building the Right Preclinical Evidence to Progress Towards the Clinic
Determine what a fit-for-purpose preclinical package should look like by benchmarking safety, toxicity, biodistribution and dosimetry strategies. Understand which studies provide decision-critical evidence and how much is truly enough to progress confidently towards clinical development.
Benchmarking Against the Organizations Defining the Future of TRPs
Learning from global pharma, emerging biotech, leading clinical centres, regulators and investors as they share the latest scientific breakthroughs, preclinical progress and strategies driving the next generation of radiopharmaceuticals.
Explore the Full Event Guide
- 100+ RLT Experts across discovery, preclinical development, drug design, imaging, dosimetry & safety
- 20+ Expert Speakers from leading pharma, biotech, academia & regulatory
- 2 Brand-New Interactive Workshops tackling cross-modality target mining & kinetic imaging for target validation
- 20+ Hours of Structured Networking to build and foster connections from the very first day
- Brand New FDA regulatory insights from former EX-FDA specialist
- The Industry’s Only Forum Dedicated Exclusively to RLT Target Selection & Drug Design
Attending Companies Include
Explore the Agenda
Discover the target selection, drug design and preclinical strategies to identify differentiated targets, optimize next-generation radiopharmaceuticals and build the evidence needed to progress towards the clinic.
Partner With Us
Position your expertise in front of 100+ discovery and preclinical RLT leaders actively seeking technologies, services and specialist partners across target discovery, drug design, imaging, radiochemistry, preclinical development, dosimetry, and safety.
Join RLT Experts
Join 100+ radiochemists, biologists, drug designers, and R&D leaders advancing next-generation radioligand therapies from discovery through translation.